-
-
Henlius Receives Positive CHMP Opinion for HANSIZHUANG as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer
2024-09-21
·HANSIZHUANG (serplulimab) is the world’s first anti-PD-1 mAb for first-line treatment of ES-SCLC -·HANSIZHUANG (serplulimab) is expected to become the first and only anti-PD-1 monoclonal antibody available in Europe for first-line treatment of ES-SCLC -·HANSIZHUANG (serplulimab) has already been approved in China, Indonesia, Cambodia, and Thailand, benefit
-
-
Fosun Pharma announces NMPA approval for Daxxify®, Marking the license-in of the world’s first and only peptide-powered botulinum toxin product to Mainland China
2024-09-11
(September 10, 2024, Shanghai, China) On September 9, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma” or “the Group”; Stock Code: 600196.SH; 02196.HK) announced that the Biologics License Application (“BLA”) for the licensed product RT002 (DaxibotulinumtoxinA-lanm, Chinese trademark:达希斐®, English trademark: DAXXIFY®, hereina
-
-
Fosun International Received HSI ESG Rating of AA- for Two Consecutive Years Selected as a Constituent Stock of the Hang Seng Corporate Sustainability Benchmark Index for Five Consecutive Years
2024-09-10
Hang Seng Indexes Company recently announced its latest Sustainability Ratings of listed companies. Fosun International Limited (HKEX stock code: 00656, “Fosun International”) with its outstanding sustainability performance, has received its rating of AA- for two consecutive years, reflecting the high recognition of Fosun International’s performance in the ESG (Environmental
-
-
[Company Results Featured Interview] Globalization and Innovation Fuel Fosun International's Steady Profits and Share Price Upside Potential
2024-09-06
In the first half of 2024, the global macroeconomic environment remained challenging. However, Fosun International (00656), which recently announced its interim results, steadfastly pushed forward its strategic focus. As a result, its four core subsidiaries, namely Yuyuan, Fosun Pharma, Fosun Insurance Portugal and Fosun Tourism Group (“FTG”),
-
-
Fosun’s Management: Globalization + Innovation + Asset-light Operations for Sustained and Stable Profits
2024-08-29
On 29 August 2024, Guo Guangchang, Chairman of Fosun International stated at the Fosun International 2024 interim results presentation that Fosun aims to build a consumer group centered on core industries, ensuring more predictable development and profits. At both the group level and within each business unit, Fosun is committed to creating corporate value for
-
-
Fosun International: Total Revenue for the First Half of 2024 Reaches RMB97.84 Billion, Industrial Operation Profit Amounts to RMB 3.47 Billion
2024-08-28
Fosun International Announces 2024 Interim Results: Powered by Core Strengths, Focus on Core Businesses and Reinforce Organic Growth Momentum 2024 Interim Results Highlights:·Total revenue maintained growth, reaching RMB97.84 billion;·Industrial operation profit maintained growth, reaching RMB3.47 billion;·Continued focus on core businesses, with the four core subsi
-
-
Fosun Pharma Announces 2024 Interim Results Breakthroughs for Innovative Products Going Overseas with Global Operation Capabilities Continuing to Strengthen
2024-08-27
(August 27, 2024, Shanghai China) On August 27, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma” or “the Group”; Stock Code: 600196.SH; 02196.HK),announced its operating performance for the first half of 2024 (the "Reporting Period"). During the Reporting Period, Fosun Pharma achieved revenue of RMB20.46 billion, an increase of 5.31% Y
-
-
Henlius Maintains Patient-Centric Focus, Drives Sustainable Growth, and Accelerates Overseas Expansion in 2024 H1
2024-08-26
Shanghai, China, August 26, 2024 – Henlius (2696.HK) announced its 2024 interim results. During the reporting period, Henlius’ revenue reached about RMB2.7461 billion, representing an increase of 9.8% YoY, and recorded a net profit of RMB386.3 million, up by 61.0% YoY. The solid and sustained profitability is due to increasing commercial sales
-
-
Fosun Tourism Announces 2024 Interim Results: Focuses on Asset-light Operations and Captures Global Growth Momentum
2024-08-23
Results Highlights:•Business Volume[1]reached RMB10,649 million, with year-on-year growth of 11%, while revenue increased by 6% year-on-year to RMB9,415 million•Club Med's performance hits record high, with Business Volume valued at RMB8,894 million, representing an increase of 10% year-on-year•Atlantis Sanya's Business Volume reached RMB866 mill